Establishment of Planning and Innovation Divisions
Goal to Launch at Least One Flagship Product Annually
Hanmi Group has unveiled its long-term vision under the catchphrase "Again, Creation and Innovation." The company plans to expand its healthcare business and focus on new drugs for obesity and anti-aging, aiming to achieve 5 trillion won in sales by 2030.
Hanmi Group is continuing its presentations at the corporate briefing session held on the 4th at Hanmi C&C Square in Songpa-gu, Seoul, targeting major securities analysts and investors. Hanmi Pharmaceutical
On December 4, Hanmi Group held its "Hanmi Vision Day" corporate briefing session at Hanmi C&C Square in Songpa-gu, Seoul, targeting major securities analysts and investors. During the event, the group announced its 2030 growth strategy roadmap, centered on four key areas: obesity, anti-aging, digital healthcare, and robotics.
Hanmi Science presented a growth strategy that restructures its existing business into two main areas: "Hanmi Pharmaceutical" (including Beijing Hanmi and Hanmi Fine Chemical), which will focus on new drugs and biopharmaceuticals, and "non-pharmaceutical business units" (JVM, Online Pharm, medical devices, and consumer healthcare).
To realize this vision, Hanmi Group has established two new divisions within its holding company, Hanmi Science: the Planning and Strategy Division and the Innovation Division, both designed to discover future business opportunities and maximize strategic growth. These divisions, directly established by Hanmi Science Vice Chairman Kim Jaekyo, serve as the group's control towers for executing its strategies.
Hanmi Pharmaceutical has set a target to achieve 1.9 trillion won in domestic sales and 1 trillion won in overseas sales by 2030, for a total of 2.9 trillion won. The company aims to launch at least one flagship product each year with annual sales exceeding 10 billion won. Key products to be developed include "Amoprel," a one-third dose antihypertensive drug launched this year; "Efeglenatide," a glucagon-like peptide-1 (GLP-1) class obesity treatment; and the "Rolontis Auto Injector."
The company is also actively pursuing partnerships and joint marketing initiatives with global pharmaceutical companies to strengthen its business advantage. Hanmi has already established joint sales systems with Samsung Bioepis and Boehringer Ingelheim, and plans to further expand partnerships with global pharmaceutical firms in the future.
The group also released its shareholder-friendly policies. It will implement a minimum dividend system and operate a minimum total shareholder return rate system to return profits from growth to shareholders. Hanmi Science plans a total shareholder return rate of 30%, Hanmi Pharmaceutical 20%, and JVM 20% or more.
Vice Chairman Kim stated, "This business portfolio restructuring is a strategic choice to diversify Hanmi Group's growth axes and strengthen its future competitiveness. We will further advance our core capabilities in new drugs and biopharmaceuticals, while generating new growth engines in our non-pharmaceutical business units to expand the group's business linkage structure."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
